PMS59 THE CLINICAL AND ECONOMIC BURDEN OF NONADHERENCE WITH OSTEOPOROSIS MEDICATIONS  by Hiligsmann, M et al.
A444 Paris Abstracts
of quality of life with VCF patients after balloon kyphoplasty (BKP) was conﬁrmed 
in a randomised controlled trial (Fracture REduction Evaluation (FREE) trial). Objec-
tive of this study was to examine a cost-effectiveness of BKP in comparison with con-
servative medical management (CMM) for VCF in patients with osteoporosis in Japan. 
METHODS: A disease event simulation model was used to estimate a lifetime cost-
effectiveness of BKP compared to CMM for female VCF patients (70-year-old) with 
osteoporosis in Japan. Payer’s perspective was employed and only medical costs were 
estimated. BKP material price was set at JPY500,000 (a3650, a1  JPY137). Utilities 
were obtained from the FREE trial. Costs and quality-adjusted life years (QALYs) 
occurring beyond 1 year were discounted at 3% per year. Cost-effectiveness was 
evaluated by ICER (Incremental Cost Effectiveness Ratio). RESULTS: BKP was associ-
ated with increased QALYs (0.308 QALYs) compared to CMM. The incremental 
cost-effectiveness ratio for BKP compared to CMM was JPY1,399,947 (a10,219) per 
QALY gained. Probabilistic sensitivity analysis indicated a 76% likelihood that BKP 
would be considered cost-effective in Japan with a willingness to pay of up to JPY 
6 million (a43,796) per QALY gained. CONCLUSIONS: Compared to CMM, BKP 
for Japanese VCF patients was projected to improve QALYs and regarded as 
cost-effective.
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OBJECTIVES: To evaluate the cost-utility of different treatment strategies in the 
treatment of severe RA after the treatment failure with ﬁrst anti-TNF therapy (FATT). 
Before the treatment failure with FATT, patients are assumed to be treated with the 
FIN-RACo combination (methotrexate, sulfasalazine, hydroxychloroquine, and pred-
nisolone). METHODS: The cost-effectiveness of treatment strategies is compared in 
a group of hypothetical Finnish RA patients. After the treatment failure with FATT, 
the patients receive either best supportive care (BSC: intramuscular gold followed by 
cyclosporine and methotrexate) or one of the following treatments before BSC: ritux-
imab, etanercept, adalimumab or inﬂiximab. Further treatments are added to the most 
cost-effective strategy in a stepwise manner. The analysis is performed on an Excel-
based Markov state transition model using the probabilistic approach. The clinical 
outcomes related to treatments are estimated from published clinical trials using 
adjusted indirect comparison. The quality adjusted life-years (QALY) gained are esti-
mated on the basis of Health Utilities Index (HUI-3) and disease severity scores (HAQ). 
The resource use and costs are obtained from the Finnish treatment practice, a pub-
lished study of hospitalisations in RA, Finnish Unit Cost list and Finnish Medicine 
Tariff. RESULTS: The treatment with rituximab dominates adalimumab and etaner-
cept after the failure of FATT as it is more effective and less costly. A QALY gained 
with rituximab or inﬂiximab costs a32,083 or a38,490 compared to BSC, respectively. 
The ICERs are a53,606; a54,722 and a37,169 per QALY gained for adding adalim-
umab, etanercept and inﬂiximab to the rituximab strategy, respectively. According 
to the cost-effectiveness acceptability frontier only the treatments with rituximab or 
rituximab followed by inﬂiximab should be considered after the failure of FATT, if 
a50,000 per QALY gained is used as a willingness-to-pay threshold. CONCLUSIONS: 
Treatment with rituximab is a cost-effective 2nd line biologic treatment strategy in 
RA patients in Finland.
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OBJECTIVES: Poor compliance and failure to persist with osteoporosis medications 
are common, but the clinical and economic consequences have not been well 
described. This study aims to estimate the clinical and economic burden of nonadher-
ence with oral bisphosphonates in osteoporotic patients and to examine the scope for 
adherence-enhancing interventions. METHODS: A validated Markov microsimula-
tion model estimated costs and outcomes (i.e. the number of fractures and the 
quality-adjusted life-year (QALY)) for three adherence scenarios: no treatment, real-
world adherence and full adherence over three years. Simulated patients matched the 
populations where osteoporosis medications are reimbursed. The real-world adher-
ence scenario employed adherence data from a published Belgian observational study 
and adherence was divided into persistence and compliance. The incremental cost per 
QALY gained was estimated comparing the three adherence scenarios. We also 
examined the clinical and economic implications of adherence-enhancing interven-
tions assuming that adherence failure would be reduced by 10%, 20% or 30%. 
RESULTS: The estimated number of fractures prevented and the lifetime QALY 
gained in the real-world adherence scenario represents only 42.0% and 41.9% to 
that obtained under full adherence scenario, respectively. The cost per QALY gained 
of real-world adherence versus no treatment was estimated at a11,175, and full 
adherence was found to be cost-saving compared to real-world adherence. An inter-
vention that decreases adherence failure by 20% was associated with a 28% increase 
in the number of fractures prevented and the costs per QALY gained compared to 
real-world adherence were respectively a29,350 and a46,275 if the intervention costs 
a100 and a150 per year. CONCLUSIONS: This study suggests that more than half 
of the potential beneﬁts from oral bisphosphonates in patients with osteoporosis are 
lost due to poor compliance and failure to persist. Depending on its cost, interven-
tions that improve adherence to therapy have the potential to be an attractive use of 
resources.
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OBJECTIVES: Because little is known about the cost effectiveness of exercise therapy, 
general practitioners lack the knowledge to apply the most cost effective treatment to 
patients with the patellofemoral pain syndrome (PFPS). Therefore, we aimed to deter-
mine the cost effectiveness of exercise therapy (intervention group) compared to ‘usual 
care’ (control group) in adolescents and young adults dealing with PFPS in primary 
care. METHODS: This multicenter prospective cost-utility analysis was conducted at 
38 general practices and 3 sport medical advice centers in The Netherlands for 2007. 
A total of 131 patients between 14 and 40 years of age presenting with symptoms of 
PFPS and no history of previous active treatment were recruited. Direct medical and 
productivity costs were included for the follow up duration of one year. RESULTS: 
The annual direct medical costs per patient were signiﬁcantly higher for the interven-
tion group (a434) compared to the control group (a299), mainly caused by additional 
physiotherapy visits. Productivity costs amounted to a577 (SD2384) and a867 
(SD2192) for the two groups respectively, resulting in annual societal costs per patient 
which were signiﬁcantly lower in the intervention group (a 1,011 versus a1.166). 
Productivity costs due to reduced efﬁciency at paid work were responsible for 47% 
of the total costs in the intervention and 56% and in the control group. Patients in 
the intervention group experienced a slightly, but not signiﬁcantly, higher quality of 
life (0.8722 versus 0.8617). CONCLUSIONS: When only direct medical costs were 
included, average costs per quality adjusted life year (QALY) were a12,754. However, 
with a societal average cost effectiveness ratio of –a14,738 per QALY, exercise therapy 
appears to be cost effective as compared to ‘usual care’. The intervention was domi-
nant in 52% of the cases (positive health effects and cost savings) and inferior in 
14%.
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OBJECTIVES: Herniated discs (HDs) and depression place a signiﬁcant burden on 
employers. Although less prevalent, fractures may also have associated burden. The 
objective of this study was to evaluate the burden of fractures compared to HD and 
depression in terms of short-term disability (STD). METHODS: A descriptive retro-
spective analysis was conducted to assess STD associated with fractures (hip, non-
vertebral composite, vertebral). Medstat/MarketScan’s Health and Productivity 
Management data from 2003–2007 were used. All patients were 45–64 year-old 
employees, stratiﬁed by gender. Fracture-related STD was deﬁned as STD absence 7 
days prior to 14 days after the date of ﬁrst diagnosis of fracture. Cases were matched 
with a control with HD and a control with depression by age, gender, occupation, 
region, insurance type, and years of STD eligibility. RESULTS: HD and depression 
incidence was 30 and 55 per 1000 patient-years, respectively. Fracture incidence 
ranged from 0.6 cases for hip to 7 cases for nonvertebral fractures per 1,000 patient-
years. However, a higher proportion of fracture patients had an STD absence com-
pared to HD and depression controls. The proportion of events with an STD absence 
in women was 16.4% vs. 5.1%, 16.5% vs. 3.5%, and 11.8% vs. 5.4% for hip, non-
vertebral, and vertebral fractures vs. depression, respectively. For men, the rates were 
30.6% vs. 5.1%, 23.6% vs. 5.9%, and 23.7% vs. 6.7%. Comparison to HD controls 
yielded similar results. All p-values were 0.01. Among fracture patients, the mean 
days of STD absence (MDA) ranged from 93 (nonvertebral) to 148 (hip). The MDA 
was signiﬁcantly higher (p  0.05) in women for vertebral (vs. HD controls) and in 
men for hip (vs. both controls), vertebral (vs. depression controls), and non-vertebral 
fractures (vs. depression controls). CONCLUSIONS: Although fracture incidence is 
lower than HDs or depression, fractures produce signiﬁcantly higher STD burden per 
event in 45–64 year-old employees.
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OBJECTIVES: To determine indirect costs of RA and investigate factors potentially 
associated with higher indirect costs. METHODS: A mail survey was carried out 
among working age Rheumatoid Arthritis (RA) patients members of one RA patients’ 
association in France. Information on demographics, disease parameters, past and 
on-going treatments and employment status was collected. In addition, two validated 
instruments, Health Assessment Questionnaire (HAQ) and the EuroQoL-5 Dimension 
were considered. Annual indirect costs including sick leaves and RA-early retirement 
were valued from the French Health Insurance perspective. Two multiple logistic 
regression models were run to explain respectively the probability of having positive 
